Company intelligence / Profile preview

Granada

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Granada Bio is an early-stage biotechnology company focused on developing novel therapeutics for metabolic and aging-related diseases. The company leverages a proprietary platform to identify and modulate key metabolic pathways that decline with age. By targeting these fundamental biological processes, Granada Bio aims to restore metabolic health and extend the healthy lifespan of patients. Their current research efforts are centered on pre-clinical programs that utilize both small molecule and protein-based approaches to address unmet needs in the metabolic health space.

Therapeutic areas: Metabolic DisordersOther
Modalities: Small moleculeProtein
Industry: Biotech

Beyond the preview

Go deeper on Granada.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Granada.

Explore the full profile